Clinical Validity of Electric Field Induced Release and Measurement (efirm) for Kras Mutation Detection in Circulating Dna Associated with Pancreatic Ductal Adenocarcinoma.

David T. Wong,Jason Hieu Tang,Wooil Kwon,Moonsoo Park,Xiaoqian Wang,Karolina Kaczor-Urbanowicz,Michael Tu,Fang Wei,Jin-Seok Heo,David Chia,Yong Kim
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e15702
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e15702 Background: Incidence of pancreatic cancer has been significantly increasing over the years and likely to become 2nd most common cause of caner death as early as 2020. One of main reasons for the high mortality rate of pancreatic cancer is the lack of sensitive and specific tools to detect in early stages. Developing an effective and credible assay platform will fill an unmet need in cancer screening and early detection. We have recently demonstrated, in two blinded independent clinical studies, the clinical utility and performance of Electric Field Induced Release and Measurement (EFIRM)-based detection of actionable EGFR mutations in plasma and saliva from non-small cell lung carcinoma (NSCLC) patients with near 100% concordance with tissue biopsy-based genotyping. We hypothesize this novel and biopsy-concordant technology is translatable to the detection/risk assessment of pancreatic ductal adenocarcinoma (PDAC). Methods: We have developed EFIRM probes for the top four KRAS mutations (G12D, G12V, G12R and G12C with > 90% frequency in total) associated with PDAC. Detection efficiency of probes for mutated KRAS was verified and optimized and subsequently tested with genomic DNA harboring a respective mutation. Results: EFIRM KRAS probes were designed and efficiency in detecting a single base KRAS mutation was optimized by utilizing synthetic oligo DNAs. Specificity and sensitivity has been further optimized by hybridization conditions, particularly by applying different electric potentials. EFIRM KRAS mutation assay efficiently differentiated a single point KRAS mutation from a wild type in sheared cellular genomic DNA harboring each of the four KRAS mutations. EFIRM is a novel detection platform ready for clinical verification to detect KRAS mutations in resectable PDAC plasma/serum samples with matched tissues. Conclusions: We have developed novel EFIRM cell free DNA KRAS assays that has a promising clinical utility as a credible, sensitive and noninvasive clinical tool in screening the patients for endoscopic evaluation and for potential prognostic/management of PDAC.
What problem does this paper attempt to address?